Equillium acquires Bioniz Therapeutics in all-stock deal

68
11
Favorite

Equillium acquires Bioniz Therapeutics in all-stock deal

seekingalpha2022-02-16

Equillium(NASDAQ:EQ)acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront payment of ~...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（11）

ITNerd
·2022-02-16
Nice
Reply
1
Report
KYBoo
·2022-02-16
Good
Reply
2
Report
AllFathers
·2022-02-16
Like
Reply
4
Report
Tgbdisciple
·2022-02-16
Cool
Reply
2
Report
Megaverse
·2022-02-16
👌🏼 yea
Reply
3
Report
MicandPotter
·2022-02-16
Wow.
Reply
5
Report
Kiattt
·2022-02-16
Like
Reply
6
Report
卖女孩的小火柴v
·2022-02-16
Ok
Reply
3
Report
plasticbag
·2022-02-16
Ok
Reply
3
Report
IronKid79
·2022-02-16
ok
Reply
1
Report
Aoooo
·2022-02-16
Pls like
Reply
3
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1187181772?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-16 20:23","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1187181772","market":"us","top_or_hot":-1,"title":"Equillium acquires Bioniz Therapeutics in all-stock deal","media":"seekingalpha","content":"<div>\n<p>Equillium(NASDAQ:EQ)acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront payment of ~...</p>\n\n<a href=\"https://seekingalpha.com/news/3800621-equillium-acquires-bioniz-therapeutics-in-all-stock-deal\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Equillium acquires Bioniz Therapeutics in all-stock deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEquillium acquires Bioniz Therapeutics in all-stock deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-16 20:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3800621-equillium-acquires-bioniz-therapeutics-in-all-stock-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Equillium(NASDAQ:EQ)acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront payment of ~...</p>\n\n<a href=\"https://seekingalpha.com/news/3800621-equillium-acquires-bioniz-therapeutics-in-all-stock-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EQ","symbol_name":"Equillium Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3800621-equillium-acquires-bioniz-therapeutics-in-all-stock-deal","article_id":"1187181772","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187181772","pubTimestamp":1645014234,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Equillium(NASDAQ:EQ)acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all curr","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EQ":"Equillium Inc."},"translate_title":"Equillium以全库存交易收购Bioniz Therapeutics","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQ":0.9},"content_text":"Equillium(NASDAQ:EQ)acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront payment of ~5.7M unregistered EQ shares issuable to Bioniz stockholders, which represents ~19.3% of Equillium’s outstanding stock.~97% of the issued EQ stock is subject to a standard 6-month lock-up provision and thereafter will be released ratably each month over the next 6 months.Equillium is also obligated to pay Bioniz stockholders up to $57.5M in potential development milestone payments across 3 clinical candidates starting with first U.S. marketing approval, and up to $250M in sales milestone payments based on BNZ-1 achieving calendar year global net sales of $500M-2B.EQ does not have third-party obligations with respect to milestones or royalties related to the Bioniz portfolio.Equillium has sole discretion over the timing and extent of advancing clinical development of the Bioniz products.Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. Bioniz was estimated to have modestly positive net working capital at closing.Through the acquisition, EQ significantly expands its immunology pipeline with a diversified portfolio of first-in-class immuno-inflammatory drug candidates.Alexandre Kaoukhov, SVP and head of clinical development at Bioniz, joins EQ as SVP of clinical development to oversee development of the Bioniz assets.Bioniz founder and CEO Nazli Azimi will be retained as an advisor to EQ while other key research and clinical personnel from Bioniz will transition to Equillium.Following the acquisition, Dolca Thomas, chief medical officer and executive VP of R&D at Equillium, will leaved the firm.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9094017494,"gmtCreate":1645021766082,"gmtModify":1676533987296,"author":{"id":"3586341894652753","authorId":"3586341894652753","name":"ITNerd","avatar":"https://static.tigerbbs.com/db0211ca9ea8852ce606418ee5492671","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586341894652753","authorIdStr":"3586341894652753"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094017494","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094039311,"gmtCreate":1645018286969,"gmtModify":1676533986776,"author":{"id":"3581501341719005","authorId":"3581501341719005","name":"KYBoo","avatar":"https://static.tigerbbs.com/43072e3bdf1be8a6c0fb9e0d7c8a0558","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581501341719005","authorIdStr":"3581501341719005"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094039311","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094098271,"gmtCreate":1645016878749,"gmtModify":1676533986617,"author":{"id":"4089502927615680","authorId":"4089502927615680","name":"AllFathers","avatar":"https://static.tigerbbs.com/919bc5fbaa10bcac5c605f3188081ff1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4089502927615680","authorIdStr":"4089502927615680"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094098271","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094098014,"gmtCreate":1645016783959,"gmtModify":1676533986606,"author":{"id":"3575247585577854","authorId":"3575247585577854","name":"Tgbdisciple","avatar":"https://static.tigerbbs.com/7c099c9cab7661dd2fa5c44752e05414","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3575247585577854","authorIdStr":"3575247585577854"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094098014","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094007549,"gmtCreate":1645015408568,"gmtModify":1676533986300,"author":{"id":"3576278607547570","authorId":"3576278607547570","name":"Megaverse","avatar":"https://static.itradeup.com/news/0bc7f9365fb6866c5d290efdfb79d160","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576278607547570","authorIdStr":"3576278607547570"},"htmlText":"👌🏼 yea&nbsp;","listText":"👌🏼 yea&nbsp;","text":"👌🏼 yea","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094007549","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094005599,"gmtCreate":1645014917875,"gmtModify":1676533986242,"author":{"id":"4091094368146990","authorId":"4091094368146990","name":"MicandPotter","avatar":"https://static.tigerbbs.com/14189ff6391ed25527aaaacdc6e48ee5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091094368146990","authorIdStr":"4091094368146990"},"htmlText":"Wow.","listText":"Wow.","text":"Wow.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094005599","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094002671,"gmtCreate":1645014699001,"gmtModify":1676533986217,"author":{"id":"3575378956741249","authorId":"3575378956741249","name":"Kiattt","avatar":"https://community-static.tradeup.com/news/e6d09fa1316db5994a40917a273216eb","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":6,"crmLevelSwitch":1,"idStr":"3575378956741249","authorIdStr":"3575378956741249"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094002671","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094002804,"gmtCreate":1645014688605,"gmtModify":1676533986217,"author":{"id":"3581562038507991","authorId":"3581562038507991","name":"卖女孩的小火柴v","avatar":"https://static.tigerbbs.com/ba918be4c84fbffa0546cae2b23bfbb7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581562038507991","authorIdStr":"3581562038507991"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094002804","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094002386,"gmtCreate":1645014558013,"gmtModify":1676533986209,"author":{"id":"3585042599146244","authorId":"3585042599146244","name":"plasticbag","avatar":"https://static.tigerbbs.com/75759bfc97d94798a8f93df583a58523","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3585042599146244","authorIdStr":"3585042599146244"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094002386","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094006559,"gmtCreate":1645014446533,"gmtModify":1676533986202,"author":{"id":"3568442933030394","authorId":"3568442933030394","name":"IronKid79","avatar":"https://static.tigerbbs.com/90b6012bb4cb2fa7d0af82b2101550ed","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":4,"crmLevelSwitch":1,"idStr":"3568442933030394","authorIdStr":"3568442933030394"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094006559","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9094006239,"gmtCreate":1645014422840,"gmtModify":1676533986194,"author":{"id":"3581502720246704","authorId":"3581502720246704","name":"Aoooo","avatar":"https://static.tigerbbs.com/8a55f0501cbdfc571393f5474dc9ace2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581502720246704","authorIdStr":"3581502720246704"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9094006239","repostId":1187181772,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":68,"commentSize":11,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}